GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Book Value per Share

Relief Therapeutics Holding (XSWX:RLF) Book Value per Share : CHF3.93 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Book Value per Share?

Relief Therapeutics Holding's book value per share for the quarter that ended in Jun. 2024 was CHF3.93.

During the past 12 months, Relief Therapeutics Holding's average Book Value Per Share Growth Rate was -49.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -20.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Relief Therapeutics Holding was 69.60% per year. The lowest was -60.00% per year. And the median was -3.75% per year.

Relief Therapeutics Holding's current price is CHF3.98. Its book value per share for the quarter that ended in Jun. 2024 was CHF3.93. Hence, today's PB Ratio of Relief Therapeutics Holding is 0.96.

During the past 13 years, the highest P/B Ratio of Relief Therapeutics Holding was 56.93. The lowest was 0.10. And the median was 0.86.


Relief Therapeutics Holding Book Value per Share Historical Data

The historical data trend for Relief Therapeutics Holding's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Book Value per Share Chart

Relief Therapeutics Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.71 8.26 17.65 13.20 4.17

Relief Therapeutics Holding Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.40 13.20 7.72 4.17 3.93

Competitive Comparison of Relief Therapeutics Holding's Book Value per Share

For the Biotechnology subindustry, Relief Therapeutics Holding's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's PB Ratio distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's PB Ratio falls into.



Relief Therapeutics Holding Book Value per Share Calculation

Relief Therapeutics Holding's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(52.23-0.00)/12.54
=4.16

Relief Therapeutics Holding's Book Value Per Share for the quarter that ended in Jun. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(49.27-0.00)/12.54
=3.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Relief Therapeutics Holding  (XSWX:RLF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Relief Therapeutics Holding Book Value per Share Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines